ECNP in depth: interviews (2016 & 2015)

November 2016

John Geddes, United Kingdom 
GeddesFor over 15 years, John Geddes, Professor of epidemiological psychiatry at the University of Oxford, has been getting to grips with the state of bipolar disorder treatment. Today, his research studies existing treatments that could give novel insights into disease mechanisms, generating paths to the discovery of new treatments. John Geddes, 2016 ECNP Neuropsychopharmacology Award winner. Geddes received the award for his exceptional research contributions to bipolar disorder and mood instability.
Read complete interview

John Geddes also gave a Plenary Award Lecture at the 29th ECNP Congress in Vienna on the topic of 'Rediscovering drug discovery in Bipolar disorder'. 
Watch the lecture here

September 2016

Silvana Galderisi, Italy
Silvana_GalderisiSilvana Galderisi is professor of psychiatry and director of the Training School in Psychiatry at the University of Naples SUN, Italy, and director of the Emergency Unit of the Department of Mental Health. As a leading figure in schizophrenia research, Professor Galderisi has an important role in many leading organisations. Impressively, she is Chair of the ECNP Schizophrenia Network, the European Psychiatric Association (EPA) Section on Schizophrenia and the World Psychiatric Association (WPA) Section on Neuroimaging. What’s more, she is President Elect of the EPA, taking on the mantle of leadership next year.
We spoke to Professor Galderisi to dive into her exemplary career in schizophrenia.
Read complete interview

August 2016

Magnus Ingelman-Sundberg, Sweden
Magnus_Ingelman_SundbergProfessor Ingelman-Sundberg has held the position of Professor of Molecular Toxicology at the Karolinska Institutet since 1996, and he currently leads a research programme focusing on genetic and epigenetic factors of importance for interindividual differences in drug response and adverse drug reactions. His lifelong career in biochemistry, molecular toxicology and pharmacology has led to the discovery of many of the genetic bases for interindividual variation in cytochrome P450 enzymes as central to drug metabolism, and Magnus Ingelman-Sundberg’s work is increasingly relevant today as psychiatry teeters on the brink of personalised therapy.
Read complete interview

June 2016

Suzanne Dickson, Sweden
dicksonSuzanne Dickson is Professor of Physiology and Neuroendocrinology at The Sahlgrenska Academy, University of Gothenburg, Sweden. A leading figure in the neurobiology of appetite, her work has particular focus on how food intake and feeding behaviour is controlled. Much of her emphasis is on the effect of endocrine and metabolic signals, chiefly ghrelin – a gastrointestinal hormone recognised as having a major influence on energy balance. 
Read complete interview 

May 2016

Harriet de Wit, USA
De_WitAmong her many mantles, Harriet de Wit is a fellow of the American College of Neuropsychopharmacology, and Professor at the Department of Psychiatry and Behavioral Neuroscience at the University of Chicago, where she heads the Human Behavioural Pharmacology Laboratory. Her lab studies the behavioural effects of a number of psychoactive drugs on human volunteers, constructing a picture of the risk and resilience factors in the development of drug abuse, including genetics, stress, and environmental context. In conversation with ECNP, she described her work and the role MDMA could play in the future of psychotherapy. 
Read complete interview

April 2016

Andreas Reif, Germany 
Andreas ReifAndreas Reif heads the department of Psychiatry, Psychosomatic Medicine and Psychotherapy at University Hospital Frankfurt, Germany. With a deep involvement in ECNP’s ADHD network, and the many projects it encompasses, he described how such collaborations came about and why a broad approach can be helpful in answering psychiatry’s big questions.
Read complete interview 


March 2016

Elisabeth Binder, Germany 
BinderStudying the epigenetics of stress is helping us to understand how it can impact individuals differently. "These environment-gene interactions are far-reaching," says Elisabeth Binder, Managing Director of the Max Planck Institute’s Department of Translational Research, "but we are on the right path to grasping their role in a number of psychiatric disorders." 
Dr Binder spoke to ECNP about her work, the future of psychiatric research, and its unanswered questions. 
Read complete interview

August 2015

Tom Insel, USA
Thomas InselTom Insel is the Director of the US National Institute for Mental Health. The ECNP invited Dr Insel to visit our annual Nice Workshop, where he spoke to a packed audience of young researchers. 
Read complete interview